Compound Hit Analysis for MSD Patients to Investigate and Optimize Novel Therapies
| Reference number | |
| Coordinator | Pixl Bio AB |
| Funding from Vinnova | SEK 2 853 668 |
| Project duration | January 2026 - January 2029 |
| Status | Ongoing |
| Venture | European Joint Programme on Rare Diseases |
| Call | International collaborations with preclinical therapy studies of rare diseases |
Purpose and goal
CHAMPION aims to develop therapies for Multiple Sulfatase Deficiency (MSD), a rare fatal neurodegenerative childhood disorder with no curative treatment. Building on screening of 5,632 compounds identifying 56 promising candidates. Goals: (1) validate compounds in vitro in cell models, (2) develop suitable formulations, (3) test efficacy in vivo in MSD mice, (4) establish PK/PD profiles, (5) elucidate mechanisms of action, and (6) evaluate potential for other lysosomal disorders.
Expected effects and result
The project expects to deliver at least one validated lead compound with demonstrated in vivo efficacy, suitable formulation and early PK/PD data, providing a foundation for future preclinical and clinical development. Additionally, expected to identify mechanisms of action, potential for orphan drug designation, and applicability to other sulfatase deficiencies and lysosomal disorders. The project may attract industry partners or public funding for continued development toward clinical trials.
Planned approach and implementation
The project comprises 6 experimental work packages (WP) over 36 months: WP1 validates 56 compounds in vitro in MSD cell models using phenomics, sulfatase activity and toxicity assays. WP2 develops formulations for selected candidates. WP3 tests efficacy in vivo in MSD mice. WP4 establishes PK/PD models. WP5 elucidates mechanisms of action via multi-omics. WP6 evaluates applicability to other lysosomal disorders. The consortium includes patient organization and regulatory/development expertise.